These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 29298160)

  • 21. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
    Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
    Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.
    Assassi S; Wang X; Chen G; Goldmuntz E; Keyes-Elstein L; Ying J; Wallace PK; Turner J; Zheng WJ; Pascual V; Varga J; Hinchcliff ME; Bellocchi C; McSweeney P; Furst DE; Nash RA; Crofford LJ; Welch B; Pinckney A; Mayes MD; Sullivan KM
    Ann Rheum Dis; 2019 Oct; 78(10):1371-1378. PubMed ID: 31391177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis.
    Oyama Y; Barr WG; Statkute L; Corbridge T; Gonda EA; Jovanovic B; Testori A; Burt RK
    Bone Marrow Transplant; 2007 Sep; 40(6):549-55. PubMed ID: 17646844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
    McSweeney PA; Nash RA; Sullivan KM; Storek J; Crofford LJ; Dansey R; Mayes MD; McDonagh KT; Nelson JL; Gooley TA; Holmberg LA; Chen CS; Wener MH; Ryan K; Sunderhaus J; Russell K; Rambharose J; Storb R; Furst DE
    Blood; 2002 Sep; 100(5):1602-10. PubMed ID: 12176878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
    Mielcarek M; Furlong T; O'Donnell PV; Storer BE; McCune JS; Storb R; Carpenter PA; Flowers ME; Appelbaum FR; Martin PJ
    Blood; 2016 Mar; 127(11):1502-8. PubMed ID: 26764356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study.
    Nash RA; McSweeney PA; Crofford LJ; Abidi M; Chen CS; Godwin JD; Gooley TA; Holmberg L; Henstorf G; LeMaistre CF; Mayes MD; McDonagh KT; McLaughlin B; Molitor JA; Nelson JL; Shulman H; Storb R; Viganego F; Wener MH; Seibold JR; Sullivan KM; Furst DE
    Blood; 2007 Aug; 110(4):1388-96. PubMed ID: 17452515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous stem cell transplantation in systemic sclerosis: a systematic review.
    Host L; Nikpour M; Calderone A; Cannell P; Roddy J
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):198-207. PubMed ID: 28869416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation.
    Burt RK; Traynor AE; Pope R; Schroeder J; Cohen B; Karlin KH; Lobeck L; Goolsby C; Rowlings P; Davis FA; Stefoski D; Terry C; Keever-Taylor C; Rosen S; Vesole D; Fishman M; Brush M; Mujias S; Villa M; Burns WH
    Blood; 1998 Nov; 92(10):3505-14. PubMed ID: 9808541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients-High Efficacy of Rituximab.
    Gernert M; Tony HP; Fröhlich M; Schwaneck EC; Schmalzing M
    Front Immunol; 2021; 12():817893. PubMed ID: 35111167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
    Burt RK; Milanetti F
    Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
    Mata JR; Zahurak M; Rosen N; DeZern AE; Jones RJ; Ambinder AJ
    Transplant Cell Ther; 2024 Jun; 30(6):588-596. PubMed ID: 38521411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.
    Keyes-Elstein L; Pinckney A; Goldmuntz E; Welch B; Franks JM; Martyanov V; Wood TA; Crofford L; Mayes M; McSweeney P; Nash R; Georges G; Csuka ME; Simms R; Furst D; Khanna D; Clair EWS; Whitfield ML; Sullivan KM
    Arthritis Care Res (Hoboken); 2023 Feb; 75(2):307-316. PubMed ID: 34533286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
    Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
    Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.
    Sullivan KM; Majhail NS; Bredeson C; Carpenter PA; Chatterjee S; Crofford LJ; Georges GE; Nash RA; Pasquini MC; Sarantopoulos S; Storek J; Savani B; St Clair EW
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):1961-1964. PubMed ID: 29953945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.
    Henrique-Neto Á; Vasconcelos MYK; Dias JBE; de Moraes DA; Gonçalves MS; Zanin-Silva DC; Zucoloto TG; de Oliveira MFC; Dotoli GM; Weffort LF; Leopoldo VC; Oliveira MC
    Adv Rheumatol; 2021 Feb; 61(1):9. PubMed ID: 33549135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.